Attached To Carbohydrate Compound; Derivative Thereof (e.g., Dna, Nucleotide, Nucleoside, Sugar, Starch, Tannin, Saccharide, Polysaccharide, Cellulose, O-, N- And S-glycoside, Vitamin B12) Patents (Class 424/1.73)
  • Patent number: 10322195
    Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the 18F isotope F is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: June 18, 2019
    Assignee: Merck & CIE
    Inventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Simon Mensah Ametamey, Cindy Ramona Fischer, Viola Groehn
  • Patent number: 10304006
    Abstract: A method and system for predicting the onset of a disease is provided.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: May 28, 2019
    Assignee: THE CHARLES STARK DRAPER LABORATORY, INC.
    Inventors: Nirmal Keshava, Laura Jane Mariano
  • Patent number: 10272112
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: April 30, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Patent number: 10217247
    Abstract: Method for generating contrast agent concentration map from a non-contrast enhanced Computed Tomography scan, a contrast enhanced Computed Tomography scan and corresponding spectral Computed Tomography data, comprising: a. Generating at least two different primary contrast agent concentration maps out of the non-contrast enhanced Computed Tomography scan, the contrast enhanced Computed Tomography scan and the spectral Computed Tomography data, b. Performing a local quality analysis of each primary contrast agent concentration map c. Determining local volumetric weights for each primary contrast agent concentration map based on the local quality analysis, and d. Generating a secondary contrast agent concentration map based on the two primary contrast agent concentration maps and on their corresponding local volumetric weights.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: February 26, 2019
    Assignee: KONINKLIJKE PHILIPS N.V.
    Inventor: Raz Carmi
  • Patent number: 10117596
    Abstract: A method to determine presence of a disease condition in a medical patient by evaluating conductivity information. Point-attributes values obtained from highly accurate conductivity data-sets taken as a function of time, over a period of time, are compared to previously determined threshold values. Z-scores may be determined to combine a plurality of point-attribute values in formulation of a composite score for a patient. Sometimes, z-scores are weighted by overall accuracy of the point-attribute in predicting presence of the disease.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: November 6, 2018
    Assignee: PROLUNG, INC.
    Inventors: Steven C Eror, Michael A Garff
  • Patent number: 10046057
    Abstract: There are disclosed compositions and methods to render nucleic acids resistant to nuclease digestion while maintaining sequence selective hybridization competency. The approach relies on utilizing nucleic acids as the polar head group of a nucleic acid-polymer amphiphile in order to assemble well-defined, discrete micellar nanoparticles. Dense packing of nucleic acid in the micelle corona allows for hybridization of complementary oligonucleotides while prohibiting enzymatic degradation.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: August 14, 2018
    Assignee: The Regents of the University of California
    Inventors: Erick T. Tatro, Nathan Gianneschi, Anthony M. Rush
  • Patent number: 9958450
    Abstract: An object of the present invention is to provide a method for accurately evaluating the specific incorporation of D-glucose into cells. The present invention as a means for achieving the object is characterized by comprising contacting a D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells and an L-glucose derivative that has a fluorescent chromophore in the molecule with different cells in the same cell strain to be evaluated, respectively, comparing the fluorescence emitted by the D-glucose derivative that has a fluorescent chromophore in the molecule and is specifically incorporated into cells with the fluorescence emitted by the L-glucose derivative that has a fluorescent chromophore in the molecule, and evaluating the specific incorporation of D-glucose into cells relative to L-glucose by taking the difference between the two kinds of fluorescence intensities.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: May 1, 2018
    Assignee: HIROSAKI UNIVERSITY
    Inventors: Katsuya Yamada, Tadashi Teshima, Toshihiro Yamamoto
  • Patent number: 9879318
    Abstract: The present invention provides methods and compositions useful for supplying high throughput nucleic acid sequencing systems with templates. The methods circumvent the need for costly, labor-intensive cloning and cell culture methods and can be scaled to accommodate template production for a variety of sequencing applications, e.g., sequencing individuals' genomes, sequencing subpopulations of transcripts from a gene of interest, and/or gene expression profiling. Particularly preferred embodiments of the methods vastly improve the preparation of cDNA from mRNA samples, e.g., by randomizing errors introduced during the process, thereby allowing these errors to be readily distinguished from true variants present in the mRNA samples.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: January 30, 2018
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Igor Vilfan, Stephen Turner
  • Patent number: 9731032
    Abstract: Aptamers consisting of a single stranded nucleic acids having 100 nucleotides or less that specifically binds to tumor initiating cancer cells are described. The aptamers can be identified by screening a large pool of randomly generated aptamers to obtain a discrete set of aptamers that specifically bind to tumor initiating cancer cells, such as those found in brain cancer or glioblastoma. The aptamers can also be linked or complexed with anticancer agents or imaging agents for use in therapy or diagnosis.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: August 15, 2017
    Assignee: The Cleveland Clinic Foundation
    Inventors: Jeremy N. Rich, Youngmi Kim, Anita B. Hjelmeland
  • Patent number: 9669118
    Abstract: The invention provides a conjugate of a biologically active molecule and a 5-fluoro-5-deoxypentose or a 3-fluoro-3-deoxypentose, wherein the biologically active molecule is selected from the group consisting of proteins, peptides, nucleic acids, oligosaccharides and polysaccharides.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: June 6, 2017
    Assignees: UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS, TURIN YLIOPISTO
    Inventors: David O'Hagan, Xiang-Guo Li
  • Patent number: 9562113
    Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: February 7, 2017
    Assignee: Bellerophon BCM LLC
    Inventors: Fuqiang Ruan, Thomas L. Deckwerth, Martin D. Meglasson
  • Patent number: 9255121
    Abstract: Provided are adenosine analog compounds such as that act as P2Y receptors, e.g., the P2Y2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: February 9, 2016
    Assignee: MICRODOSE THERAPEUTX, INC.
    Inventors: Efrat Ben-Zeev, Vincent Jacques, Yael Marantz, A. Sekar Reddy, Zhaoda Zhang, Oren Becker, Dilara McCauley, Pini Orbach, Sharon Shacham, Ashis K. Saha, Michael Xie
  • Publication number: 20150132221
    Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 14, 2015
    Inventors: Leonard F. Pease, Hedieh Saffari, Gerald J. Gleich, Kristin M. Leiferman, Kathryn A. Peterson, Russell Morris Condie
  • Publication number: 20150133777
    Abstract: The invention disclosed herein discloses selected ribose isomers that are useful as PET probes (e.g. [18F]-2-fluoro-2-deoxy-arabinose). These PET probes are useful, for example, in methods designed to monitor physiological processes including ribose metabolism and/or to selectively observe certain tissue/organs in vivo. The invention disclosed herein further provides methods for making and using such probes.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 14, 2015
    Inventors: Owen Witte, Peter M. Clark, Blanca Graciela Flores Castillo, Michael E. Jung, Nikolai M. Evdokimov
  • Publication number: 20150118157
    Abstract: Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. 1.1A and 1.1B having formula 2, 3, 4, 5, 11, and 12 and formula 2?, 4?, and 11?,as well as uses for the compounds for imaging, and the like.
    Type: Application
    Filed: January 6, 2015
    Publication date: April 30, 2015
    Inventors: Mohammad Namavari, Sanjiv Sam Gambhir, Beverly S. Mitchell
  • Patent number: 9011817
    Abstract: Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. 1.1A and 1.1B having formula 2, 3, 4, 5, 11, and 12 and formula 2?, 4?, and 11?, as well as uses for the compounds for imaging, and the like.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: April 21, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mohammad Namavari, Sanjiv Sam Gambhir, Beverly S. Mitchell
  • Patent number: 9005580
    Abstract: Methods for treating renal cancer by administration of certain 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide compounds, especially 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide (Orellanine), conjugated to an alpha-emitting radionuclide (e.g. Astatine-211) to increase the efficacy of the formulation and/or a large molecule (e.g. a oligomer/polymer such as a PEG or a polysaccharide such as a dextran or a Ficoll®) to reduce the filtration and consequently the renal exposure. Particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods can be used.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: April 14, 2015
    Assignee: Oncorena AB
    Inventors: Borje Haraldsson, Ulf Nilsson, Lisa Buvall, Jenny Nystrom
  • Patent number: 8974848
    Abstract: Tooth stain resulting from exposure to coloring agents contained in food and beverages, generally termed foodstuffs, is reduced, prevented and/or reversed by the addition of consumable anti-staining materials to the foodstuff anytime prior to ingestion. The anti-staining materials may be introduced into the foodstuff during the manufacturing process or added by the consumer at the time of preparation or use. A number of materials which interact with tooth stains and/or staining agents to counteract their effect and/or reduce their coloration as well as substances which interact with teeth to block the interaction of staining agents with teeth are disclosed.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: March 10, 2015
    Inventors: Barry W. Carothers, Donald N. Riggs
  • Patent number: 8974766
    Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: March 10, 2015
    Assignee: Bellerophon BCM LLC
    Inventors: Fuqiang Ruan, Thomas L. Deckwerth, Martin D. Meglasson
  • Patent number: 8968760
    Abstract: A method for attaching an implant to tissue is disclosed. In embodiments, a method includes applying a sprayable material to tissue, the sprayable material possessing functional groups capable of binding to tissue. The sprayable material also possesses functional groups capable of binding to an implant. In embodiments, the functional groups capable of binding to an implant include nucleotides. In such a case, the implant possesses complementary nucleotides capable of binding to the nucleotides on the sprayable material, thereby permitting hydrogen binding between the two. The implant may thus be affixed to tissue, and repositioned as necessary, prior to more permanent attachment utilizing means such as sutures, tacks, etc.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: March 3, 2015
    Assignee: Covidien LP
    Inventors: Timothy Sargeant, Jonathan Thomas
  • Patent number: 8969546
    Abstract: Provided in the following specification are precursors or synthons that are useful for the synthesis of various arabinose based chemical and radiochemical derivatives of nitroimidazole-containing azomycin arabinosides, such as radioiodinated 1-#-D-(5-deoxy-5-[I*]-iodoarabinofuranosyl)-2-nitroimidazole (*IAZA), and radiofluorinated 1-#-D-(5-deoxy-5-[18F]-iodoarabinofuranosyl)-2-nitroimidazole (18FAZA). Such compounds are useful in imaging, therapy, or radiotherapy. Further, various syntheses of said precursors/synthons and the incorporation of said precursors/synthons into kits is provided. The precursors/synthons provided herein allow for an improved and facile manufacturing process for nitroimidazole-containing azomycin arabinosides.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: March 3, 2015
    Assignees: The Governors of the University of Alberta, Alberta Health Services
    Inventors: Piyush Kumar, Leonard Wiebe, Alexander McEwan
  • Publication number: 20150056136
    Abstract: The invention relates to products and methods that provide increased yields of certain radiopharmaceuticals.
    Type: Application
    Filed: April 10, 2013
    Publication date: February 26, 2015
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, James F. Castner
  • Publication number: 20150044136
    Abstract: The invention described herein relates to the composition of a liquid in which a silver ion moiety can act as a preservative as well as an astringent for the inhibition of microbial infections of the eye.
    Type: Application
    Filed: August 12, 2013
    Publication date: February 12, 2015
    Inventors: George H. Scherr, Seth I. Kaplan
  • Patent number: 8952072
    Abstract: Methods of treating malnutrition are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: February 10, 2015
    Assignee: LiveLeaf, Inc.
    Inventors: Alexander L Huang, Gin Wu
  • Patent number: 8946304
    Abstract: Methods of treating malnutrition are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: February 3, 2015
    Assignee: LiveLeaf, Inc.
    Inventors: Alexander L Huang, Gin Wu
  • Patent number: 8945509
    Abstract: Magnetic beads that include polyvalent ligands comprising various carbohydrates are described. Methods for fabricating such magnetic beads are also provided as well as methods of their use to capture and enrich pathogen cell population for subsequent culture, lysis and identification.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: February 3, 2015
    Assignee: Life Technologies Corporation
    Inventors: Aldrich Lau, Robert Eason, Maxim Brevnov, Handong Li, Kevin Hacker
  • Patent number: 8940714
    Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: January 27, 2015
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
  • Publication number: 20150023875
    Abstract: The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 28, 2014
    Publication date: January 22, 2015
    Applicants: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Omid C. Farokhzad, Jianjun Cheng, Robert S. Langer, Benjamin A. Teply, Stephen E. Zale
  • Publication number: 20150023876
    Abstract: A method of diagnosing a CD206 expressing cell-related disorder by administering a pharmaceutical composition to a subject, the composition including a carrier molecule having a detectable moiety attached thereto. The carrier molecule has a dextran backbone, and at least one receptor substrate conjugated, directly or indirectly, to the dextran backbone, wherein the receptor substrate is chosen so as to specifically bind to CD206. A method of treating a CD206 expressing cell-related disorder is also provided, as well as an ex vivo method and kit for quantitating the number of cells expressing CD206 in a bodily fluid.
    Type: Application
    Filed: July 22, 2014
    Publication date: January 22, 2015
    Inventors: Frederick O. Cope, Michael S. Blue, Wendy L. Metz, Larry S. Schlesinger
  • Publication number: 20150017098
    Abstract: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells.
    Type: Application
    Filed: October 20, 2011
    Publication date: January 15, 2015
    Inventors: Junji Kato, Rishu Takimoto
  • Patent number: 8932558
    Abstract: Provided herein are methods and compositions for the in vitro formation of multi subunit biological platforms. The biological platforms may be used to screen chemical or biological compounds, in particular compounds that may disrupt or otherwise affect the formation of the multi subunit complexes, or disrupt already-formed in vitro assembled multi subunit complexes. Also provided herein are methods and compositions for the in vivo formation of multi-subunit biological complexes. The methods and compositions described herein may be used to develop animal models of diseases or disorders.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: January 13, 2015
    Assignee: Plaxgen Inc
    Inventor: Shanmugavel Madasamy
  • Patent number: 8926943
    Abstract: The present invention provides a method for the generation of 223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said 223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted 223Ra solution; iv) loading the 223Ra of the first eluted 223Ra solution onto a strong acid cation exchange resin; and v) eluting the 223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: January 6, 2015
    Assignee: Algeta ASA
    Inventors: Jan Roger Karlson, Peer Børretzen
  • Publication number: 20140314671
    Abstract: Embodiments of the present disclosure provide for labeled probes such as labeled maltose probes and labeled acarbose probes, methods of making labeled probes, pharmaceutical compositions including labeled probes, methods of using labeled probes, methods of diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, kits for diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, and the like.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 23, 2014
    Inventors: Mohammad Namavari, Gayatri Gowrishankar, Sanjiv S. Gambhir
  • Publication number: 20140308203
    Abstract: Provided herein are methods for delivering a molecule in situ to a cell and for treating a cancer via the in situ delivery. The methods comprise contacting or administering to the cell, as two separate components, a morpholino oligonucleotide comprising a targeting moiety followed by a single wall nanotube construct comprising second morpholino oligonucleotides complementary to the first morpholino oligonucleotides and one or both of a therapeutic or diagnostic payload molecule linked to the single wall nanotube construct. Upon self-assembly of a single wall nanotube complex via hybridization of the first morpholino and second complementary morpholino oligonucleotides at the cell, the payload molecule is delivered. Also provided is the two component self-assembly single wall nanotube system and the single wall nanotube construct comprising the second component.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 16, 2014
    Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
  • Patent number: 8858916
    Abstract: A compound comprising a metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent is provided. The compound is suitable for imaging by single-photon emission computed tomography, computer assisted tomography, magnetic resonance spectroscopy, magnetic resonance imaging, positron emission tomography, fluorescence imaging or x-ray.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: October 14, 2014
    Assignee: Mallinckrodt LLC
    Inventor: Dennis A. Moore
  • Patent number: 8846003
    Abstract: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: September 30, 2014
    Assignee: Symic Biomedical, Inc.
    Inventors: Alyssa Panitch, John E. Paderi, Kinam Park, Katherine Stuart, Steve Higbee
  • Patent number: 8845999
    Abstract: Radiolabeled tracers for sodium/glucose cotransporters (SGLTs), their synthesis, and their use are provided. The tracers are methyl or ethyl pyranosides having an equatorial hydroxyl group at carbon-2 and a C 1 preferred conformation, radiolabeled with 18F, 123I, or 124I, or free hexoses radiolabeled with 18F, 123I, or 124. Also provided are in vivo and in vitro techniques for using these and other tracers as analytical and diagnostic tools to study glucose transport, in health and disease, and to evaluate therapeutic interventions.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: September 30, 2014
    Assignee: The Regents of the University of California
    Inventors: Ernest M. Wright, Jorge R. Barrio, Bruce A. Hirayama, Vladimir Kepe
  • Publication number: 20140271470
    Abstract: The present invention relates to methods of diagnosing and treating prostate cancer, including metastatic prostate cancer. Related pharmaceutical compositions are also provided.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Laurel O. Sillerud, David L. Vander Jagt, Lorraine Deck
  • Publication number: 20140255307
    Abstract: The present invention relates to contrast medium composition and a method of bio imagination using the same. The contrast medium composition of the present invention includes a biomolecule, DNA nanostructure, as an active ingredient, is fundamentally non-cytotoxic and non-immunogenic and is not likely to induce safety problems that may be observed in other organic or inorganic contrast medium composition. In addition, the contrast medium composition of the present invention not only facilitates diagnosis of disease through sufficient contrast enhancement effect by showing excellent cellular uptake and intracellular stability and can visualize even SLNs which is difficult to be visualized traditionally, so can judge metastasis of cancer easily and apply lower invasive treatment.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Dae Ro AHN, Se Hoon KIM
  • Patent number: 8828355
    Abstract: Disclosed are compositions and methods for imaging in animals.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: September 9, 2014
    Assignee: University of Utah Research Foundation
    Inventors: Charles Keller, Patrick J. Hawkes
  • Publication number: 20140248212
    Abstract: Embodiments of the invention include a PET/SPECT reporter gene system that uses enhanced non-immunogenic versions of a human mitochondrial thymidine kinase 2 expressed in cytoplasm to preferentially trap novel PET/SPECT radiolabeled L and D-enantiomer analogs of the natural substrate thymidine. Such highly sensitive, non-immunogenic reporter genes function in combination with a set of novel, radiolabeled probes in whole body molecular imaging applications using positron emission tomography (PET) or single photon emission computed tomography (SPECT).
    Type: Application
    Filed: August 6, 2012
    Publication date: September 4, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Caius G. Radu, Johannes Czernin, Dean O. Campbell, Shahriar S. Yaghoubi, Nagichettiar Satyamurthy, Arnon Lavie
  • Patent number: 8822545
    Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: September 2, 2014
    Assignee: LiveLeaf, Inc.
    Inventors: Alexander L Huang, Gin Wu
  • Patent number: 8822544
    Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.
    Type: Grant
    Filed: March 22, 2014
    Date of Patent: September 2, 2014
    Assignee: Liveleaf, Inc.
    Inventors: Alexander L Huang, Gin Wu
  • Publication number: 20140234217
    Abstract: The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject. Components of the targeted delivery compositions are put together through duplex formation between oligonucleotides.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 21, 2014
    Inventor: Thomas Edward Rogers
  • Publication number: 20140234216
    Abstract: The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method of production and their use in diagnostic and therapeutic medical applications, such as diagnostic nuclear imaging and radionuclide therapy.
    Type: Application
    Filed: August 10, 2012
    Publication date: August 21, 2014
    Applicant: MERCK & CIE
    Inventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Harriet Struthers, Viola Groehn, Simon Mensah Ametamey, Cindy Ramona Fischer
  • Patent number: 8809399
    Abstract: Methods of treating gastrointestinal spasms are provided. For example, methods of treating gastrointestinal spasms are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: August 19, 2014
    Assignee: Liveleaf, Inc.
    Inventors: Alexander L Huang, Gin Wu
  • Publication number: 20140227182
    Abstract: Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter and astrocyte elevated gene 1 (AEG-1) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols, e.g. for imaging and/or treating spontaneous metastasis. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.
    Type: Application
    Filed: February 18, 2014
    Publication date: August 14, 2014
    Applicants: THE JOHNS HOPKINS UNIVERSITY, VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Martin Gilbert POMPER, Hyo-eun BHANG, Paul FISHER
  • Publication number: 20140219916
    Abstract: This invention provides a combination of a DNA strand/fragment and isotope therapy that is applied to a cancerous tissue to selectively kill cancer cells with minimal negative effects on surrounding non-cancerous cells. Linear DNA fragments with labeled isotope are able to be absorbed by the tumor cells and bind the tumor cell's DNA through recombination, and then the isotope kills the tumor cells. Illustratively, a gene or a DNA fragment is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. The illustrative embodiment produces the compound/agent containing a DNA fragment and P-32 through use of conventional P-32 labeling techniques such as those employed in molecular biology experiments (for example experiments used to test gene expression and gene amplification potency). The same P-32 labeled DNA can be employed directly for cancer treatment through a novel medical treatment method.
    Type: Application
    Filed: February 4, 2014
    Publication date: August 7, 2014
    Inventors: Yanping Kong, Jinhong Liu
  • Publication number: 20140219917
    Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 7, 2014
    Applicants: Emory University, Georgia State Research Foundation, Georgia Tech Research Corporation
    Inventors: Niren MURTHY, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
  • Publication number: 20140193337
    Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the 18F isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.
    Type: Application
    Filed: August 21, 2012
    Publication date: July 10, 2014
    Applicant: MERCK & CIE
    Inventors: Roger Schibli, Rudolf Moser, Cristina Magdalena Muller, Simon Mensah Ametamey, Cindy Ramona Fischer, Viola Groehn